Pharmaceutical Excipients for Hot-Melt Extrusion - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Excipients for Hot-Melt Extrusion
The authors examine the influence of glass-transition temperature, melt viscosity, degredation temperature, and process settings.


Pharmaceutical Technology
Volume 35, Issue 5, pp. 74-82

References

1. M.M. Crowley et al., Drug Dev. Ind. Pharm. 33 (9), 909–926 (2007).

2. I. Ghebre-Sellassie and C. Martin, Pharmaceutical Extrusion Technology (Informa Healthcare, New York, Vol. 133, 2007).

3. J. Breitenbach, Eur. J. Pharm. Biopharm. 54 (2), 107–117 (2002).

4. J.E. Patterson et al., Int. J. Pharm. 336 (1), 22–34 (2007).

5. A. Foster, J. Hempenstall, and T. Rades, J. Pharm. Pharmacol. 53 (3), 303–315 (2001).

6. A. Forster et al., Int. J. Pharm. 226 (1–2), 147–161 (2001).

7. J.E. Patterson et al., Drug Dev. Ind. Pharm. 34 (1), 95–106 (2008).

8. S. Janssens et al., Eur. J. Pharm. Sci. 30 (3–4), 288–294 (2007).

9. S. Janssens and G. Van den Mooter, "Enhancing Solubility and Dissolution Rate of Poorly Soluble Drugs," WO 2007/115381, Oct. 2007.

10. E. Karavas et al., Eur. J. Pharm. Biopharm. 63 (2), 103–114 (2006).

11. R.J. Chokshi et al., J. Pharm Sci. 94 (11), 2463–2474 (2005).

12. S. Thumma et al., Eur. J. Pharm. Biopharm. 70 (2), 605–614 (2005).

Citation: When referring to this article, please cite it as "M.Karl, D. Djuric, K.Kolter, "Pharmaceutical Excipients for Hot-Melt Extrusion," Pharmaceutical Technology 35 (5) 74-82 (2011)."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here